Krapf M - Search Results

1

Epidermal growth factor receptor and anaplastic lymphoma kinase testing and mutation prevalence in patients with advanced non-small cell lung cancer in Switzerland: A comprehensive evaluation of real world practices.

Ess SM, Herrmann C, Frick H, Krapf M, Cerny T, Jochum W, Früh M. Ess SM, et al. Among authors: krapf m. Eur J Cancer Care (Engl). 2017 Nov;26(6). doi: 10.1111/ecc.12721. Epub 2017 May 30. Eur J Cancer Care (Engl). 2017. PMID: 28557060

2

Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.

Diem S, Schmid S, Krapf M, Flatz L, Born D, Jochum W, Templeton AJ, Früh M. Diem S, et al. Among authors: krapf m. Lung Cancer. 2017 Sep;111:176-181. doi: 10.1016/j.lungcan.2017.07.024. Epub 2017 Jul 24. Lung Cancer. 2017. PMID: 28838390

3

Organ-specific response to nivolumab in patients with non-small cell lung cancer (NSCLC).

Schmid S, Diem S, Li Q, Krapf M, Flatz L, Leschka S, Desbiolles L, Klingbiel D, Jochum W, Früh M. Schmid S, et al. Among authors: krapf m. Cancer Immunol Immunother. 2018 Dec;67(12):1825-1832. doi: 10.1007/s00262-018-2239-4. Epub 2018 Aug 31. Cancer Immunol Immunother. 2018. PMID: 30171269 Free PMC article.

4

Joint Income-Wealth Inequality: Evidence from Lucerne Tax Data.

Gallusser D, Krapf M. Gallusser D, et al. Among authors: krapf m. Soc Indic Res. 2022;163(1):251-295. doi: 10.1007/s11205-022-02887-9. Epub 2022 Feb 24. Soc Indic Res. 2022. PMID: 35967250 Free PMC article.

5

Molecular characterisation of methicillin-resistant Staphylococcus pseudintermedius from dogs and the description of their SCCmec elements.

Krapf M, Müller E, Reissig A, Slickers P, Braun SD, Müller E, Ehricht R, Monecke S. Krapf M, et al. Vet Microbiol. 2019 Jun;233:196-203. doi: 10.1016/j.vetmic.2019.04.002. Epub 2019 Apr 6. Vet Microbiol. 2019. PMID: 31053353

6

Synthesis and biological evaluation of quinazoline derivatives - A SAR study of novel inhibitors of ABCG2.

Krapf MK, Gallus J, Spindler A, Wiese M. Krapf MK, et al. Eur J Med Chem. 2019 Jan 1;161:506-525. doi: 10.1016/j.ejmech.2018.10.026. Epub 2018 Oct 13. Eur J Med Chem. 2019. PMID: 30390439

7

2,4,6-Substituted Quinazolines with Extraordinary Inhibitory Potency toward ABCG2.

Krapf MK, Gallus J, Namasivayam V, Wiese M. Krapf MK, et al. J Med Chem. 2018 Sep 13;61(17):7952-7976. doi: 10.1021/acs.jmedchem.8b01011. Epub 2018 Aug 20. J Med Chem. 2018. PMID: 30075623

8

New Inhibitors of Breast Cancer Resistance Protein (ABCG2) Containing a 2,4-Disubstituted Pyridopyrimidine Scaffold.

Krapf MK, Gallus J, Vahdati S, Wiese M. Krapf MK, et al. J Med Chem. 2018 Apr 26;61(8):3389-3408. doi: 10.1021/acs.jmedchem.7b01012. Epub 2018 Apr 18. J Med Chem. 2018. PMID: 29547272

9

Synthesis and biological investigation of 2,4-substituted quinazolines as highly potent inhibitors of breast cancer resistance protein (ABCG2).

Krapf MK, Gallus J, Wiese M. Krapf MK, et al. Eur J Med Chem. 2017 Oct 20;139:587-611. doi: 10.1016/j.ejmech.2017.08.020. Epub 2017 Aug 10. Eur J Med Chem. 2017. PMID: 28841513

10

4-Anilino-2-pyridylquinazolines and -pyrimidines as Highly Potent and Nontoxic Inhibitors of Breast Cancer Resistance Protein (ABCG2).

Krapf MK, Gallus J, Wiese M. Krapf MK, et al. J Med Chem. 2017 May 25;60(10):4474-4495. doi: 10.1021/acs.jmedchem.7b00441. Epub 2017 May 12. J Med Chem. 2017. PMID: 28471656

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

26 results

Search Page

Filters